Vivek K. Jayaraman Sells 10,780 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) COO Vivek K. Jayaraman sold 10,780 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $1.55, for a total transaction of $16,709.00. Following the completion of the sale, the chief operating officer now directly owns 905,828 shares of the company’s stock, valued at $1,404,033.40. The trade was a 1.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cerus Price Performance

Shares of NASDAQ:CERS opened at $1.51 on Friday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.54. The firm has a 50-day simple moving average of $1.74 and a 200 day simple moving average of $1.80. The company has a market cap of $280.54 million, a PE ratio of -13.73 and a beta of 1.56.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The business had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. On average, sell-side analysts anticipate that Cerus Co. will post -0.08 EPS for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Institutional Investors Weigh In On Cerus

Institutional investors have recently modified their holdings of the business. Rockport Wealth LLC bought a new stake in shares of Cerus during the 4th quarter valued at about $25,000. Cibc World Markets Corp acquired a new position in Cerus during the 4th quarter valued at about $26,000. R Squared Ltd acquired a new position in Cerus during the 4th quarter valued at about $29,000. Virtu Financial LLC acquired a new position in Cerus during the 4th quarter valued at about $33,000. Finally, Dark Forest Capital Management LP acquired a new position in Cerus during the 4th quarter valued at about $34,000. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.